GI-focused healthcare company Ironwood Pharmaceuticals has announced that it plans to relocate its headquarters to a new office in downtown Boston from its current location in Cambridge. Ironwood’s new headquarters will occupy approximately 39,000 square feet at 100 Summer Street. The new Boston headquarters is sized to fit the current employee base following completion of […]

Pfizer and Array BioPharma have announced Pfizer will acquire Array, a commercial stage biopharma with operations in Colorado, Massachusetts and North Carolina focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need. Pfizer has agreed to acquire Array for $48 per share in […]

Cambridge-based Comet Therapeutics has raised $28.5 million in Series A funding to develop a broad portfolio of drug candidates built around the unique ability to re-engineer Coenzyme A (CoA)-related metabolism. Comet’s platform has numerous potential applications including metabolic disorders, neuro-metabolic diseases, immuno-metabolic conditions and other life-threatening diseases. CoEnzyme A (CoA) is essential in numerous cellular […]

Merck has announced that it plans to acquire Lexington-based Tilos Therapeutics, a biopharma developing therapeutics targeting the latent TGFβ complex for the treatment of cancer, fibrosis and autoimmune diseases. TGFβ is a potent cytokine believed to play an important role in the development of cancer and fibrotic diseases. TGFβ is secreted as a complex with […]

Vertex and CRISPR Therapeutics have expanded their collaboration and entered into an exclusive licensing agreement to discover and develop gene editing therapies for the treatment of Duchenne Muscular Dystrophy (DMD) and Myotonic Dystrophy Type 1 (DM1). In addition, Vertex will acquire privately-held Exonics, a company focused on creating transformative gene editing therapies to repair mutations […]

bluebird bio has announced that the European Commission (EC) has granted conditional marketing authorization for Zynteglo™,  a gene therapy for certain patients with transfusion-dependent β-thalassemia (TDT). The authorization is valid in all 28 member states of the EU as well as Iceland, Liechtenstein and Norway. TDT is a severe genetic disease caused by mutations in the […]